Merck Sharp + Dohme Corp.

International Flavors & Fragrances Inc.

Matthew John Clements

John S Debenham

Jeffrey John Hale

Thomas F Walsh

Robert P Belko

Tesfaye Biftu

William K Hagmann

Michael G Monteleone

Hubert B Josien

Bin Hu

Barbara A Pio

Dong-Ming Shen

Dong Xiao

Christina B Madsen-Duggan

Thomas H Graham

Yong Zhang

Cheng Zhu

Purakkattle J Biju

Helen Y Chen

Harry R Chobanian

Yan Guo

Timothy A Blizzard

Christopher W Plummer

Zhengxia Chen

Jessica Frie

Manfred Pawlak

Anilkumar G Nair

Vincent Colandrea

Timothy Allen Blizzard

Alejandro Crespo

Mingxiang Cui

Karen M Marcantonio

Andrey V Peresypkin

Louis Croce, Jr

Michael Miller

Linda L Brockunier

Duane E Demong

Roy Helmy

Tesfaye Bifu

Jessica L Frie

Vincent J Colandrea

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia. 

Antidiabetic tricyclic compounds

The present invention relates to substituted 4-hydroxypyrimidine-5-carboxamides useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.

Substituted 4-hydroxypyrimidine-5-carboxamides

Compounds of structural formula I are inhibitors of prolylcarboxypeptidase (PrCP). The compounds of the present invention are useful for the prevention and treatment of conditions related to the enzymatic activity of PrCP such as abnormal metabolism, including obesity; diabetes; metabolic syndrome; obesity related disorders; and diabetes related disorders. 

Prolylcarboxypeptidase inhibitors

The present invention relates to tetrahydro-1H-pyrrolo fused pyridone compounds useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.

Tetrahydro-1H-pyrrolo fused pyridones

3-(methoxymethyl)-2-pentylcyclopent derivative compounds having the structure set forth below are disclosed: These compounds are useful fragrance chemicals, suitable for use in creating fragrances and scents in items such as perfumes, colognes and personal care products.

Use of 3-(methoxymethyl)-2-pentylcyclopenta derivatives in perfume compositions

Growing community of inventors

Old Bridge, NJ, United States of America

Matthew John Clements